The purpose of this study is to determine whether long-acting octreotide is safe and
effective in the treatment of patients with Rendu-Osler-Weber (e.g. HHT).
The study hypothesis is that octreotide is safe and will reduce transfusion requirements and
endoscopy frequency in ROW patients with refractory anaemia due to bleeding gastrointestinal